HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Below are several companies positioning themselves to be a viable opioid alternative.
We are highlighting: Endonovo Therapeutics, Inc. (ENDV), INSYS Therapeutics, Inc. (INSY), Cara Therapeutics, Inc. (CARA), Collegium Pharmaceutical, Inc. (COLL), and Titan Pharmaceuticals, Inc. (TTNP).
According to the FDA, more than 72,000 people died from drug overdoses in 2017, including overdoses due to illicit drugs and prescription opioids. Biotech and CBD companies are both working on different solutions to this dire issue. Several of which we highlight below. The first on our list has just announced something that makes us even more intrigued than we already were. Endonovo Therapeutics, Inc. (ENDV) (Market Cap: $10.69M Share Price: $0.027) , a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, has developed a therapy that could help lessen the pain without the kinds of side effects many other opioid alternatives have. Their non-invasive easy to use ORTHOHALO™ device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation.
The announcement that peaked our interest is that ENDV has entered into a non-binding Letter of Intent with US Authentic Trading Company (USAT) to act as the exclusive partner to assist with facilitating a relationship between the Company and China. The company anticipates definitive agreements to be executed in the first quarter of 2019.
Alan Collier, CEO of Endonovo Therapeutics, stated, "With nearly eight million hospital beds in China and the increased costs and health risks associated with opioid use, I am pleased to be working with the US Authentic Trading Company to ensure SofPulse® is available throughout mainland China. The positive results in reducing pain and edema, combined with eliminating opioid use and dependency is something we are very proud of. We believe that hospitals, treatment centers and medical facilities throughout the World will benefit with SofPulse®."
China has been dealing with opioids since the 1600s, all the way back to the Opium wars. This market added to the already robust US market makes ENDV one of the most enticing opioid alternative plays on the market.
A biotech researching potential CBD treatments, INSYS Therapeutics, Inc. (INSY) (Market Cap: $395.11M Share Price: $5.32) announced results from its latest study at the American Epilepsy Society 2018 annual meeting. INSY found their pharmaceutical-grade cannabidiol (CBD) oral solution was generally well-tolerated—even at high doses—as an investigational treatment for refractory pediatric epilepsy. This is promising news for the company.
In their attempts to become a viable opioid alternative, Cara Therapeutics, Inc. (CARA) (Market Cap: $700.57M Share Price: $17.76) recently conducted preclinical rodent models, their CR701 wound up reducing hyperalgesia (sensitization of nerve ending to painful stimuli) and allodynia (painful perception of innocuous stimuli) in a setting considered comparable to human conditions.
Collegium Pharmaceutical, Inc. (COLL) (Market Cap: $641.67M Share Price: $19.30) a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from pain, released their 3rd quarter numbers last month. Some highlights include: net product revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017. Cash increased by $6.0 million, to $139.8 million as of September 30, 2018; raising year-end cash guidance to $145.0 million.
Titan Pharmaceuticals, Inc. (TTNP) (Market Cap: $22.88M Share Price: $0.29) reported third quarter 2018 results last month. During the period, Titan recorded total revenues of $1.7 million compared to $40 thousand in 3Q:17. This 3Q:18 total consisted of $1.4 million of license revenue and $244,000 in product sales of Probuphine by Titan.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve month agreement, and can be canceled at anytime by the issuer ENDV. All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
SOURCE: Regal Consulting, LLC